< 生产厂家价格 >

那格列奈

那格列奈用途

Nateglinide是胰岛素促分泌剂,可作用于非胰岛素依赖型糖尿病(NIDDM)。

点击显示

那格列奈名称

[ CAS 号 ]:
105816-04-4

[ 中文名 ]:
那格列奈

[ 英文名 ]:
Nateglinide

[中文别名 ]:

[英文别名 ]:

Glinate
Starsis
SDZ DJN 608
Starlix
DJN 608
Natelide
MFCD00875706
ay4166
Starlix DS
Fastic-d5

那格列奈生物活性

[ 描述 ]:

Nateglinide是胰岛素促分泌剂,可作用于非胰岛素依赖型糖尿病(NIDDM)。

[ 相关类别 ]:

信号通路 >> 其他 >> 其他

研究领域 >> 心血管疾病

[参考文献]

[1]. http://205.193.93.51/dpdonline/searchRequest.dodin=2245439

[2]. http://www.drugs.com/cdi/nateglinide.html

[3]. http://www.drugbank.ca/drugs/DB00731

[相关活性小分子]

那格列奈物理化学性质

[ 密度 ]:
1.1±0.1 g/cm3

[ 沸点 ]:
527.6±39.0 °C at 760 mmHg

[ 熔点 ]:
137-141ºC

[ 分子式 ]:
C₁₉H₂₇NO₃

[ 分子量 ]:
317.423

[ 闪点 ]:
272.9±27.1 °C

[ 精确质量 ]:
317.199097

[ PSA ]:
66.40000

[ LogP ]:
4.21

[ 外观性状 ]:
白色结晶粉末

[ 蒸汽压 ]:
0.0±1.5 mmHg at 25°C

[ 折射率 ]:
1.536

[ 储存条件 ]:
Room temp

那格列奈MSDS

详细MSDS(安全技术说明书)

那格列奈毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: SQ7318950

CHEMICAL NAME :: D-Phenylalanine, N-((4-(1-methylethyl)cyclohexyl)carbonyl)-, trans-

CAS REGISTRY NUMBER :: 105816-04-4

LAST UPDATED :: 199806

DATA ITEMS CITED :: 7

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD - Lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >2 gm/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - ptosis Behavioral - somnolence (general depressed activity) Gastrointestinal - hypermotility, diarrhea

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 25(Suppl 1),S5,1997

TYPE OF TEST :: LD - Lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: >2 gm/kg

TOXIC EFFECTS :: Gastrointestinal - nausea or vomiting

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 25(Suppl 1),S9,1997 ** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 90 gm/kg/13W-I

TOXIC EFFECTS :: Endocrine - changes in adrenal weight Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - phosphatases Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 25(Suppl 1),S13,1997

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 182 gm/kg/52W-I

TOXIC EFFECTS :: Gastrointestinal - changes in structure or function of salivary glands Gastrointestinal - ulceration or bleeding from stomach Nutritional and Gross Metabolic - weight loss or decreased weight gain

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 25(Suppl 1),S63,1997

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 27300 mg/kg/13W-I

TOXIC EFFECTS :: Gastrointestinal - changes in structure or function of salivary glands Liver - change in gall bladder structure or function Related to Chronic Data - death

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 25(Suppl 1),S35,1997

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 36400 mg/kg/52W-I

TOXIC EFFECTS :: Gastrointestinal - changes in structure or function of salivary glands

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 25(Suppl 1),S79,1997 ** REPRODUCTIVE DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 27 gm/kg

SEX/DURATION :: female 17-22 day(s) after conception lactating female 1-21 day(s) post-birth

TOXIC EFFECTS :: Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 25(Suppl 1),S139,1997

点击显示

那格列奈安全信息

[ 个人防护装备 ]:
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter

[ 危害码 (欧洲) ]:
Xn: Harmful;

[ 风险声明 (欧洲) ]:
R22

[ 安全声明 (欧洲) ]:
24/25-36

[ 危险品运输编码 ]:
NONH for all modes of transport

[ RTECS号 ]:
SQ7318950

[ 海关编码 ]:
2924299090

那格列奈合成路线

详细合成路线

那格列奈上下游产品

那格列奈上游产品

那格列奈下游产品

那格列奈海关

[ 海关编码 ]: 2924299090

[ 中文概述 ]:
2924299090. 其他环酰胺（包括环氨基甲酸酯）（包括其衍生物以及他们的盐）. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:30.0%

[ 申报要素 ]: 品名, 成分含量, 用途, 包装

[ Summary ]:
2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%

那格列奈文献

Formulation and in vitro evaluation of nateglinide microspheres using HPMC and carbopol-940 polymers by ionic gelation method.

Pak. J. Pharm. Sci. 26(6) , 1229-35, (2013)

This study involves the design and characterization of Nateglinide (NAT) microspheres to enhance patient compliance. Ionic gelation technique was used to prepare Nateglinide Microspheres by using rate...

From evidence assessments to coverage decisions?: the case example of glinides in Germany.

Health Policy 104(1) , 27-31, (2012)

In Germany, coverage decisions in the statutory health insurance (SHI) system are based on the principles of evidence-based medicine. Recently, an evidence assessment by the Institute for Quality and ...

Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.

Int. J. Clin. Pract. 59(10) , 1218-28, (2005)

Therapy for type 2 diabetes mellitus should aim to control not only fasting, but also postprandial glucose levels. Nateglinide, a d-phenylalanine derivative, restores postprandial early phase insulin ...

更多文献